Literature DB >> 30714298

Remission phase in children diagnosed with type 1 diabetes in years 2012 to 2013 in Silesia, Poland: An observational study.

Agata Chobot1, Joanna Stompór2, Karolina Szyda2, Magdalena Sokołowska3, Grażyna Deja2, Joanna Polańska4, Przemysława Jarosz-Chobot2.   

Abstract

BACKGROUND/
OBJECTIVE: The study aimed to analyze the frequency of partial remission (PR) and its association with chosen clinical and laboratory factors among pediatric patients with newly diagnosed type 1 diabetes (T1D). The long-term effect of PR on chosen parameters was also investigated.
METHODS: In 194 patients (95 girls) aged 8.1 ± 4.3 years, we analyzed data at T1D onset: glycemia, pH, C-peptide, antibodies, weight, and concomitant autoimmune diseases. Anthropometric parameters, daily insulin requirement (DIR), and HbA1c 2 and 4 years after T1D diagnosis were also analyzed. We determined PR based on HbA1c and DIR measurements at least every 3 months.
RESULTS: PR occurred in 59% of patients. Remitters had significantly higher pH (7.33 vs 7.28, P = 0.03), weight SD score (SDS) (0.25 vs -0.24, P = 0.002), and body mass index SDS (0.19 vs -0.66, P = 0.02) compared with non-remitters. Concomitant diseases correlated negatively with PR. Multivariate analysis indicated only pH at onset was an independent predictor of PR. pH was the most important factor associated with the beginning of PR. There was a positive correlation between the start and duration of PR. Four years after T1D onset remitters had lower HbA1c (7.24% vs 8.05%, 53 vs 63.9 mmol/mol, P < 0.001) and DIR (0.81 vs 1.08, P = 0.005).
CONCLUSIONS: PR occurred quite often and developed more frequently in children with higher: weight and BMI SDS, but the main factor influencing PR presence and duration was higher pH at T1D onset. There was a beneficial impact of PR on HbA1c and DIR after 4 years of treatment.
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  HbA1c; ketoacidosis; partial remission; type 1 diabetes

Mesh:

Substances:

Year:  2019        PMID: 30714298     DOI: 10.1111/pedi.12824

Source DB:  PubMed          Journal:  Pediatr Diabetes        ISSN: 1399-543X            Impact factor:   4.866


  5 in total

1.  Combined vitamin D, ibuprofen and glutamic acid decarboxylase-alum treatment in recent onset Type I diabetes: lessons from the DIABGAD randomized pilot trial.

Authors:  Johnny Ludvigsson; Indusmita Routray; Sriramulu Elluru; Per Leanderson; Helena E Larsson; Björn Rathsman; Ragnar Hanås; Annelie Carlsson; Torben Ek; Ulf Samuelsson; Torun Torbjörnsdotter; Jan Åman; Eva Örtqvist; Karun Badwal; Craig Beam; Rosaura Casas
Journal:  Future Sci OA       Date:  2020-06-23

Review 2.  The Remission Phase in Type 1 Diabetes: Role of Hyperglycemia Rectification in Immune Modulation.

Authors:  Rong Tang; Ting Zhong; Chao Wu; Zhiguang Zhou; Xia Li
Journal:  Front Endocrinol (Lausanne)       Date:  2019-12-03       Impact factor: 5.555

3.  CD4+CD25+CD127hi cell frequency predicts disease progression in type 1 diabetes.

Authors:  Aditi Narsale; Breanna Lam; Rosa Moya; TingTing Lu; Alessandra Mandelli; Irene Gotuzzo; Benedetta Pessina; Gianmaria Giamporcaro; Rhonda Geoffrey; Kerry Buchanan; Mark Harris; Anne-Sophie Bergot; Ranjeny Thomas; Martin J Hessner; Manuela Battaglia; Elisavet Serti; Joanna D Davies
Journal:  JCI Insight       Date:  2021-01-25

4.  Candidate Biomarkers for the Prediction and Monitoring of Partial Remission in Pediatric Type 1 Diabetes.

Authors:  Laia Gomez-Muñoz; David Perna-Barrull; Josep M Caroz-Armayones; Marta Murillo; Silvia Rodriguez-Fernandez; Aina Valls; Federico Vazquez; Jacobo Perez; Raquel Corripio; Luis Castaño; Joan Bel; Marta Vives-Pi
Journal:  Front Immunol       Date:  2022-02-23       Impact factor: 7.561

5.  Using Glycated Albumin and Stimulated C-Peptide to Define Partial Remission in Type 1 Diabetes.

Authors:  Mei Shi; Xiaolin Ji; Yuting Xie; Ting Zhong; Rong Tang; Li Fan; Xia Li
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-19       Impact factor: 6.055

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.